Competition hots up in Hep–B vaccine segment - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Competition hots up in Hep–B vaccine segment

Mar 14, 2000

Wockhardt has launched a Hepatitis B vaccine Biovac B. This is in collaboration with a German company Rhein Biotech GmbH. Wockhardt ranks fifth in terms of domestic sales with five brands among the top 250 in India. The company has among the top three R & D facilities in the country. It hived off the real estate property as well as its intravenous fluids business to its group company in the current year. Wockhardt had acquired Merind and Wallis last year.

So far the Hepatitis B segment has been dominated by SmithKline Pharma’s Engerix–B. This product has grown at an average of over 50% per year over the last three year’s. Although companies like Bharat Serum and Shanta Biotech have successful products they have not been as successful in the marketing as SmithKline. With the entry of Wockhardt, the competition in the segment is bound to hot up.

First, since Wockhardt has in place a good marketing infrastructure in place. The company has 21 clearing and forwarding agents, 2500 stockists for distribution, 1200 medical representatives which would help it market its vaccine effectively.

Second, unlike SmithKline which imports the dosages from its parent’s Belgium plant, Wockhardt manufactures the vaccine in India which would not only enable it to price its vaccine a shade below those of Engerix–B but also enjoy higher margins. This is because last year the government imposed a 38.5% import duty on vaccines, which affected SmithKline’s margins since it did not raise its vaccine prices. The company is unlikely to raise prices this year too and hence the erosion in margins is expected to continue.

Market View:
Analysts have flagged Wockhardt as a buy since it has a strong product portfolio. The company derives around 30% from products introduced in the last five year’s and only 12% of its revenues accrue from products under price control.

Equitymaster requests your view! Post a comment on "Competition hots up in Hep–B vaccine segment". Click here!


More Views on News

J.B.CHEMICALS Share Price Down by 5%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Sep 23, 2020 | Updated on Sep 23, 2020

J.B.CHEMICALS share price is trading down by 5% and its current market price is Rs 1,030. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are PFIZER (up 1.9%) and GLENMARK PHARMA (up 1.5%). The top losers are J.B.CHEMICALS (down 5.3%) and JUBILANT LIFE SCIENCES (down 6.3%).

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 5%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 23, 2020 | Updated on Sep 23, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 5% and its current market price is Rs 239. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 5.2%). The top losers are LUPIN (down 0.2%) and SYNGENE INTERNATIONAL (down 0.3%).

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 23, 2020 (Close)